What is Kaleido?
Kaleido specializes in the development of innovative, personalized insulin pump systems designed to empower individuals living with diabetes. By prioritizing user-friendly technology, the company aims to provide patients with greater freedom and confidence in managing their condition. Its core value proposition lies in the intersection of advanced engineering and patient-centric design, positioning the firm as a critical player in the medical device sector. As the company continues to refine its hardware and software integration, it remains focused on delivering high-impact solutions that address the daily challenges faced by the diabetic community, thereby enhancing quality of life through precision health technology.
How much funding has Kaleido raised?
Kaleido has raised a total of $108.9M across 2 funding rounds:
Series B
$10.9M
Series D
$98M
Series B (2016): $10.9M, investors not publicly disclosed
Series D (2026): $98M led by Innovation Industries, Venturing, and ROM Utrecht Region
Key Investors in Kaleido
Innovation Industries
A European venture capital fund specializing in deep tech companies that focus on sustainability and scalability, targeting technologies with significant global impact.
Venturing
A strategic partner providing comprehensive infrastructure, including marketing and financial support, to facilitate growth and cross-sector collaboration in healthcare and technology.
ROM Utrecht Region
A regional investment entity that supports innovative entrepreneurs with financing and international market entry, specifically within the Life Sciences and Health sectors.
What's next for Kaleido?
With the successful closure of this Series D round, Kaleido is well-positioned to accelerate its international market entry and deepen its research and development capabilities. The strategic focus will likely shift toward scaling production capacity and expanding its footprint within key global healthcare ecosystems. By leveraging the expertise of its primary backers, the company is expected to navigate the regulatory complexities of the medical device industry while fostering new partnerships that integrate its insulin delivery systems into broader digital health frameworks. This phase of growth is critical for Kaleido as it seeks to solidify its competitive advantage and drive sustainable, long-term value for both its stakeholders and the patients it serves.
See full Kaleido company page
